NCT00271570View on ClinicalTrials.gov

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Kawasaki Disease
Interventions
DRUG

Infliximab (Remicade)

Remicade was 5 mg/kg IV (single dose)

BIOLOGICAL

Intravenous immunoglobulin (IVIG)

2nd dose of IVIG (2g/kg)

Trial Locations (1)

92103

Ucsd/Chhc, San Diego

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

University of California, San Diego

OTHER

NCT00271570 - Infliximab (Remicade) for Patients With Acute Kawasaki Disease | Biotech Hunter | Biotech Hunter